How do I read a peptide Certificate of Analysis (COA)?

A valid COA must include: (1) the peptide's full chemical name and CAS number; (2) the specific lot number being supplied; (3) purity result expressed as a percentage via HPLC analysis — reputable sources show ≥98%; (4) identity confirmation via LC-MS matching the theoretical molecular weight; and (5) the name of an independent, identifiable laboratory. A COA issued by the vendor itself, or one lacking a verifiable laboratory name, provides no meaningful quality guarantee.

Peptides in Europe: Cross-Border Shipping, Customs & Legality by Country

Q: What is the EMA's role in regulating peptides in Europe?

The European Medicines Agency (EMA) is the pan-European body responsible for the scientific evaluation, supervision, and safety monitoring of medicinal products in the EU. Peptides approved as medicinal products — such as semaglutide and tirzepatide — fall under EMA's centralised procedure. Research-use-only (RUO) peptides are not EMA-authorised medicines and are subject to national competent authority regulations in each member state.

Q: Which national authority oversees peptides in my country?

Each EU member state has a National Competent Authority (NCA): Spain — AEMPS; Italy — AIFA; Germany — BfArM; France — ANSM; Netherlands — CBG; Poland — URPL; Sweden — Läkemedelsverket; Ireland — HPRA. Outside the EU: United Kingdom — MHRA; Norway — DMP (Statens Legemiddelverk); Denmark — Lægemiddelstyrelsen; Switzerland — Swissmedic. Always consult the NCA for your jurisdiction and a licensed healthcare professional before use.

Q: What does 'research use only' mean?

'Research Use Only' (RUO) is a designation indicating that a substance is intended solely for in vitro or preclinical research purposes and has not been evaluated for safety or efficacy in human or veterinary therapeutic applications. RUO peptides are not approved medicines. Their use outside controlled research settings, and especially in humans without medical supervision, is unsupported by any regulatory framework and carries significant risk.

Country Directory

The European Compendium — Entries by Country

Denmark

National Competent Authority: Lægemiddelstyrelsen (DKMA)

RegulatorLægemiddelstyrelsen — Danish Medicines Agency (DKMA)

Websitelaegemiddelstyrelsen.dk

LanguageDanish (da)

EU MemberYes — EMA centralised procedure applies

Denmark applies EU pharmaceutical law. Medicinal peptides require marketing authorisation via EMA (centralised) or national procedure. Research-use-only substances are subject to import and research regulations. Verify the exact regulatory pathway with the DKMA for any intended use. Consult a licensed Danish healthcare professional.

France

National Competent Authority: ANSM

RegulatorAgence nationale de sécurité du médicament et des produits de santé (ANSM)

Websiteansm.sante.fr

LanguageFrench (fr-FR)

EU MemberYes — EMA centralised procedure applies

The ANSM supervises the safety and availability of health products in France. Approved peptide medicines follow the EMA centralised or MRP/DCP pathway. Importation of non-authorised substances for research requires specific authorisation. Always verify with ANSM and a licensed French healthcare professional.

Germany

National Competent Authority: BfArM

RegulatorBundesinstitut für Arzneimittel und Medizinprodukte (BfArM)

Websitebfarm.de

LanguageGerman (de)

EU MemberYes — EMA centralised procedure applies

Germany has a rigorous pharmaceutical regulatory framework. The BfArM handles national marketing authorisations and safety monitoring. German law (Arzneimittelgesetz — AMG) strictly governs the import, manufacture, and distribution of medicinal substances. Research use of non-authorised peptides requires formal authorisation. Consult a licensed German healthcare professional.

Ireland

National Competent Authority: HPRA

RegulatorHealth Products Regulatory Authority (HPRA)

Websitehpra.ie

LanguageEnglish (en-IE)

EU MemberYes — EMA centralised procedure applies

The HPRA is Ireland's competent authority for human medicines, veterinary medicines, medical devices, and controlled substances. It applies EU pharmaceutical law including EMA centralised procedure outcomes. Always verify with HPRA and consult a licensed Irish healthcare professional.

Italy

National Competent Authority: AIFA

RegulatorAgenzia Italiana del Farmaco (AIFA)

Websiteaifa.gov.it

LanguageItalian (it)

EU MemberYes — EMA centralised procedure applies

AIFA governs medicines regulation in Italy and participates in EMA scientific committees. Italian pharmaceutical law is strict regarding unauthorised substances. Research institutions must obtain specific authorisations for the import and use of non-approved peptides. Consult a licensed Italian healthcare professional and AIFA's official guidance.

Netherlands

National Competent Authority: CBG-MEB

RegulatorCollege ter Beoordeling van Geneesmiddelen (CBG-MEB)

Websitecbg-meb.nl

LanguageDutch (nl)

EU MemberYes — EMA centralised procedure applies

The CBG-MEB is the Dutch Medicines Evaluation Board, responsible for authorising medicines in the Netherlands. It also has a significant role in EMA processes. Dutch pharmaceutical law (Geneesmiddelenwet) governs all medicinal products. Research use of non-authorised peptides requires authorisation. Verify with CBG-MEB and consult a licensed Dutch healthcare professional.

Norway

National Authority: Statens Legemiddelverk (DMP)

RegulatorStatens Legemiddelverk (Norwegian Medicines Agency, DMP)

Websitelegemiddelverket.no

LanguageNorwegian (no)

EEA MemberYes (EEA, not EU) — applies EMA procedures via EEA Agreement

Norway is not an EU member but participates in the EEA, meaning EMA-authorised medicines are generally applicable. The DMP (Statens Legemiddelverk) handles national authorisations and enforces Norwegian pharmaceutical law (Legemiddelloven). Research use of non-approved peptides requires DMP authorisation. Consult a licensed Norwegian healthcare professional.

Poland

National Competent Authority: URPL

RegulatorUrząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych (URPL)

Websiteurpl.gov.pl

LanguagePolish (pl)

EU MemberYes — EMA centralised procedure applies

The URPL oversees registration of medicinal products, medical devices, and biocidal products in Poland. Polish pharmaceutical law (Prawo farmaceutyczne) applies. EMA-authorised medicines are valid in Poland. For research substances, specific import and use authorisations from URPL are required. Consult a licensed Polish healthcare professional.

Portugal

National Competent Authority: INFARMED

RegulatorINFARMED — Autoridade Nacional do Medicamento e Produtos de Saúde

Websiteinfarmed.pt

LanguagePortuguese (pt-PT)

EU MemberYes — EMA centralised procedure applies

INFARMED is Portugal's National Authority for Medicines and Health Products. It is responsible for the evaluation, authorisation, regulation, and safety monitoring of human and veterinary medicines in Portugal. EMA-authorised products apply. Research use requires formal INFARMED authorisation. Consult a licensed Portuguese healthcare professional.

Spain

National Competent Authority: AEMPS

RegulatorAgencia Española de Medicamentos y Productos Sanitarios (AEMPS)

Websiteaemps.es

LanguageSpanish (es-ES)

EU MemberYes — EMA centralised procedure applies

The AEMPS is Spain's national agency for medicines and medical devices, operating under Royal Decree 870/2013 and EU pharmaceutical law. It participates in EMA scientific committees and enforces marketing authorisation requirements. Peptide substances not holding an EMA or national marketing authorisation cannot legally be marketed as medicines. Research access requires formal protocols. Consult a licensed Spanish healthcare professional.

Sweden

National Competent Authority: Läkemedelsverket

RegulatorLäkemedelsverket — Swedish Medical Products Agency (MPA)

Websitelakemedelsverket.se

LanguageSwedish (sv)

EU MemberYes — EMA centralised procedure applies

The Läkemedelsverket is Sweden's medicines agency, responsible for authorisation, supervision, and monitoring of medicinal products and medical devices. Swedish pharmaceutical law (Läkemedelslagen) applies, in conjunction with EU directives. For research-use peptides, specific permits from Läkemedelsverket are required. Consult a licensed Swedish healthcare professional.

Switzerland

National Authority: Swissmedic

RegulatorSchweizerisches Heilmittelinstitut (Swissmedic)

Websiteswissmedic.ch

LanguageGerman / French / Italian (de-CH primary)

EU/EEA MemberNo — independent Swiss regulatory framework (HMG)

Switzerland maintains its own regulatory framework under the Heilmittelgesetz (HMG / Loi sur les produits thérapeutiques). Swissmedic authorises medicines independently of EMA, though Swiss and EU standards are largely aligned. Peptide substances require specific authorisation. The import and use of non-approved substances for research is subject to strict Swissmedic regulation. Consult a licensed Swiss healthcare professional.

United Kingdom

National Authority: MHRA

RegulatorMedicines and Healthcare products Regulatory Agency (MHRA)

Websitegov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

LanguageEnglish (en-GB)

EU/EEA MemberNo — post-Brexit independent UK regulatory framework

Since Brexit, the MHRA operates as Great Britain's independent medicines regulator under UK pharmaceutical law. Northern Ireland retains access to EMA procedures under the Windsor Framework. The UK has its own marketing authorisation pathways. Research use of non-authorised peptide substances requires MHRA authorisation. Consult a licensed UK healthcare professional.

The Pan-EU Angle

Buying Peptides in the EU: Cross-Border Shipping, Customs & Legality by Country

The EU single market makes it easy to assume that a peptide legal to receive in one member state is legal everywhere in the bloc. It is not. Legality, customs enforcement, and shipping risk are set at national level for anything outside the EMA's centralised medicines list, so the same parcel can clear customs without incident in one country and be inspected, delayed, or seized in another. This entry compares the pan-EU picture — what changes at the border, what stays constant, and where to verify before you order.

1Legality Is Set Nationally, Not Centrally

Only peptides authorised as medicines through the EMA's centralised procedure — semaglutide among them — carry a single, bloc-wide legal status; semaglutide is prescription-only, and obtaining it without a valid prescription is illegal anywhere in the EU. Research-use-only peptides fall outside that framework entirely. Each National Competent Authority (see the country directory above) sets its own rules for import, possession, and research use, so a substance treated as a routine research reagent in one country can require specific authorisation in a neighbouring one. Retatrutide, for example, is not EMA-authorised anywhere in the EU and remains in clinical trials only — no country in this compendium offers a legitimate retail pathway to it.

2Intra-EU Shipments

Parcels moving between EU member states benefit from the customs union: goods that have already cleared entry into the EU generally move without a further customs declaration. That does not make intra-EU shipments risk-free. National postal and customs authorities retain the right to inspect any parcel, and pharmacologically active substances without adequate documentation can still be flagged, regardless of which EU country the parcel started in.

3Extra-EU Shipments & Customs Risk

Shipments entering the EU from outside it — including from the United Kingdom or non-European suppliers — are subject to a customs declaration and can be opened, delayed, or seized if the contents are undeclared, mislabelled, or lack supporting documentation. Norway's EEA membership eases access to EMA-authorised medicines but does not exempt research-use shipments from Norwegian customs review. Switzerland and the UK each run independent customs regimes, so a shipment legal to send from one may still be examined on arrival in the other.

4EMA vs. National Agencies: Who Decides

The EMA sets the pan-European standard for authorised medicines, but it has no authority over research-use-only substances or customs enforcement — that sits with each country's National Competent Authority and customs service. When legality or shipping risk falls outside what the EMA framework covers, the deciding authority is always national. Checking the specific NCA entry for both the origin and destination country, in the directory above, is the only way to know where a shipment actually stands.

None of the above replaces independent verification. A Certificate of Analysis does not change a shipment's legal status, but it is still the only practical way to confirm what a cross-border parcel actually contains once it arrives — see how to read a peptide COA and the country-by-country verification overview for the practical steps.

View Verified Sources

Affiliate link · Informational only — no sales, no medical advice.

Regulatory Framework

The EMA Pan-European Framework

01 — Centralised Procedure

What the EMA Authorises

The European Medicines Agency coordinates the scientific evaluation of medicinal products for the EU. Peptides that qualify as medicinal products and are authorised by EMA receive a single marketing authorisation valid in all EU member states, plus Iceland, Liechtenstein, and Norway. The EMA's EPAR database lists all authorised medicinal products.

02 — National Procedures

Mutual Recognition & Decentralised

For medicines not requiring the centralised procedure, the Mutual Recognition Procedure (MRP) and Decentralised Procedure (DCP) allow marketing authorisations to be granted in multiple member states simultaneously. National competent authorities coordinate the review and grant individual national marketing authorisations.

03 — Research-Use Only

RUO Substances & the Regulatory Gap

Peptides sold as "research use only" (RUO) are not EMA-authorised medicines. They are not subject to EMA review and do not carry any marketing authorisation. They exist in a gap between chemical substance regulation and pharmaceutical law. Each member state's NCA determines the applicable rules for import, storage, and research use. No EU-wide RUO framework exists.

04 — Verification Imperative

Why Independent COA Matters

Without EMA authorisation, there is no mandatory quality control. Independent third-party analysis (HPLC for purity ≥98%, LC-MS for identity confirmation) is the only available mechanism to verify what a substance actually contains. A COA from the vendor's own laboratory does not constitute independent verification. The laboratory must be identifiable and independently verifiable.

05 — Medical Supervision

The Non-Negotiable Step

Regardless of regulatory classification, the EMA and all national competent authorities are unequivocal: potent pharmacologically active substances should only be used under supervision of a licensed healthcare professional. This applies to approved medicines and, with even greater force, to non-approved research substances. This compendium does not constitute medical advice.

06 — Counterfeit Risk

The Scale of the Problem

European customs and medicines agencies consistently report seizures of counterfeit peptides. Counterfeits range from correct compound at sub-threshold purity to entirely different substances. The EMA's PROTECT programme and national NCA alerts document ongoing counterfeit activity. Independent COA analysis is the only practical tool for non-specialist verification — but it does not replace medical supervision.

Protocol

Six-Step Verification Protocol

Request the lot-specific COA

Always request the COA for the exact lot number you are receiving — not a generic document or a previous batch. Lot-level analysis is the only meaningful verification.

Verify the testing laboratory

Confirm the laboratory named on the COA is a real, identifiable, independent entity. Search for it independently. A laboratory you cannot verify independently provides no assurance.

Check HPLC purity ≥ 98%

The HPLC chromatogram should show a primary peak representing the target compound at or above 98% of total area. Lower figures indicate impurities that may be pharmacologically active.

Confirm identity by LC-MS

Liquid chromatography–mass spectrometry confirms that the compound's observed molecular mass matches the theoretical mass of the declared peptide. This rules out substitution fraud.

Check the national regulatory status

Consult the national competent authority entry in this compendium. Understand whether the substance requires specific import authorisation or research protocol approval in your jurisdiction.

Consult a licensed healthcare professional

This is not optional. Any potent pharmacologically active compound must be used under medical supervision. Verification confirms what a substance is; it does not make it safe to use unsupervised.

Frequently Asked

Reference Questions

What is the EMA's role in regulating peptides in Europe?

The European Medicines Agency coordinates the scientific evaluation of medicinal products for the EU. Peptides approved as medicines follow the EMA centralised procedure and receive a single marketing authorisation valid across all EU member states. Research-use-only peptides are not EMA-authorised and fall under national competent authority rules.

How do I read a peptide Certificate of Analysis?

A valid COA must include: the compound's full name and CAS number; a specific lot number; HPLC purity ≥98% by area; LC-MS identity confirmation; and the name of an independently verifiable laboratory. A COA issued by the vendor itself, or one lacking a verifiable laboratory name, provides no meaningful quality assurance. See the COA Anatomy section above for a field-by-field breakdown.

Which national authority oversees peptides in my country?

Each country has a National Competent Authority. Spain: AEMPS · Italy: AIFA · Germany: BfArM · France: ANSM · Netherlands: CBG-MEB · Poland: URPL · Sweden: Läkemedelsverket · Ireland: HPRA · UK: MHRA · Norway: Statens Legemiddelverk · Denmark: Lægemiddelstyrelsen · Switzerland: Swissmedic. See the full country directory above for website addresses and entry notes.

Does this site sell peptides?

No. Peptides Pan-Europe is strictly an informational and educational reference — The Compendium. We do not sell products, capture personal data for commercial purposes, or provide medical advice. The downloadable guide is a free educational resource. Always consult a licensed healthcare professional.

What purity level should a research peptide have?

Independent analytical standards consistently cite ≥98% purity (by HPLC area) as the minimum for research-grade peptides. Results below this threshold indicate impurities — potentially truncated sequences, racemised residues, or unrelated compounds — that compromise both research validity and safety. Always request LC-MS identity confirmation alongside the HPLC purity figure.

What does 'Research Use Only' mean?

'Research Use Only' (RUO) indicates a substance is intended solely for in vitro or preclinical research and has not been evaluated for safety or efficacy in human therapeutic applications. RUO peptides are not approved medicines. Their use outside controlled research settings, and especially in humans without medical supervision, is unsupported by any regulatory framework and carries significant risk.

Is it legal to buy peptides in the EU?

It depends on the specific peptide and the destination country. Peptides authorised as medicines by the EMA — semaglutide among them — require a valid prescription; obtaining semaglutide without one is illegal anywhere in the EU. Research-use-only peptides fall outside any EU-wide framework and are instead governed by each member state's National Competent Authority, so the same substance can be treated differently depending on the country. Retatrutide remains in clinical trials and is not EMA-authorised in any EU country. Always check the relevant NCA entry in this compendium and consult a licensed healthcare professional.

Will customs seize a peptide shipment in the EU?

Shipments moving between EU member states benefit from the customs union and generally move without a further declaration, though national authorities can still inspect any parcel. Shipments entering the EU from outside it are subject to a customs declaration and can be opened, delayed, or seized if the contents are undeclared, mislabelled, or lack supporting documentation. Risk is highest for research-use-only peptides, which carry no EU-wide import authorisation. A verifiable Certificate of Analysis does not change a shipment's legal status, but it helps establish exactly what a parcel contains if it is inspected.

Is the peptide regulatory framework the same in every EU country?

No. The EMA centralised procedure applies uniformly to authorised medicinal products across all EU member states plus Iceland, Liechtenstein, and Norway, but research-use-only peptides are not covered by any EU-wide rule. Each country's National Competent Authority — AEMPS in Spain, BfArM in Germany, ANSM in France, and others — sets its own import, customs, and research-use requirements, which is why the same peptide can be treated differently depending on where a shipment originates and where it is delivered. See the country directory above for the specific NCA in each jurisdiction.

The Non-Negotiable Step: Consult a Licensed Healthcare Professional

Regardless of verification outcome, no peptide — approved or research-grade — should be used in humans without supervision by a licensed healthcare professional. This compendium provides reference information only. It does not constitute medical advice, does not replace clinical consultation, and does not imply endorsement of any use case. Sources: EMA (ema.europa.eu), national competent authorities as listed per entry. Updated July 2026.

The Reference Compendium for Peptide Verification, Cross-Border Shipping & Legality in Europe

The European Compendium — Entries by Country

Buying Peptides in the EU: Cross-Border Shipping, Customs & Legality by Country

1Legality Is Set Nationally, Not Centrally

2Intra-EU Shipments

3Extra-EU Shipments & Customs Risk

4EMA vs. National Agencies: Who Decides

The EMA Pan-European Framework

What the EMA Authorises

Mutual Recognition & Decentralised

RUO Substances & the Regulatory Gap

Why Independent COA Matters

The Non-Negotiable Step

The Scale of the Problem

Anatomy of a Certificate of Analysis

Six-Step Verification Protocol

Request the lot-specific COA

Verify the testing laboratory

Check HPLC purity ≥ 98%

Confirm identity by LC-MS

Check the national regulatory status

Consult a licensed healthcare professional

From the Reference Blog

How to Read a Peptide COA: A Complete Guide

Spotting Counterfeit Peptides in Europe

Independent Lab Testing: HPLC and LC-MS Explained

The EMA Framework for Research Peptides in Europe

Peptide Verification by Country: An EU Overview

The Compendium Guide to Peptide Verification in Europe

Reference Questions

The Non-Negotiable Step: Consult a Licensed Healthcare Professional

How The Compendium Works

SPrimary Sources Only

VNo Person, No Claim

URegular Updates

CCompliance Strict